Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Heart failure

In search of improved therapies for acute heart failure

Nature Reviews Cardiology volume 8, pages 9–10 (2011)Cite this article

Subjects

Worsening renal function is common among patients hospitalized with acute heart failure and is associated with poor outcomes. Although preliminary studies suggested that adenosine receptor antagonists could preserve renal function and improve diuretic responsiveness, the A1-receptor antagonist rolofylline did not provide benefit in patients with acute heart failure in PROTECT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. AHA. Heart disease and stroke statistics: 2010 update at-a-glance [online], (2010).

  2. Jencks, S. F., Williams, M. V. & Coleman, E. A. Rehospitalizations among patients in the Medicare fee-for-service program. N. Engl. J. Med. 36 0, 1418–1428 (2009).

    Article  Google Scholar 

  3. US Department of Health and Human Services. Hospital compare database [online], (2010).

  4. Forman, D. E. et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol. 4 3, 61–67 (2004).

    Article  Google Scholar 

  5. Massie, B. M. et al. for the PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 363, 1419–1428 (2010).

    Article  Google Scholar 

  6. Gottlieb, S. S. et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105, 1348–1353 (2002).

    Article  CAS  Google Scholar 

  7. Cotter, G. et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J. Card. Fail. 14, 631–640 (2008).

    Article  CAS  Google Scholar 

  8. Cleland, J. G., Coletta, A. P. & Clark, A. L. Clinical trials update from the European Society of Cardiology Heart Failure Meeting 2010: TRIDENT 1, BENEFICIAL, CUPID, RFA-HF, MUSIC, DUEL, handheld BNP, phrenic nerve stimulation, CHAMPION and CABG with CRT study. Eur. J. Heart Fail. 12, 883–888 (2010).

    Article  CAS  Google Scholar 

  9. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287, 1531–1540 (2002).

  10. Konstam M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319–1331 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, University of Zurich, Raemistrsse 100, 8091, Zurich, Switzerland

    Frank Ruschitzka

  2. Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, 473 West 12th Avenue, Room 110P, Columbus, 43210-1252, OH, USA

    William T. Abraham

Authors
  1. Frank Ruschitzka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William T. Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William T. Abraham.

Ethics declarations

Competing interests

F. Ruschitzka has received Speakers' Bureau honoraria from Cardioventis, Merck and Co., Novartis, Pfizer, and Servier and is a stockholder/Director of Cardioventis. W. T. Abraham declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruschitzka, F., Abraham, W. In search of improved therapies for acute heart failure. Nat Rev Cardiol 8, 9–10 (2011). https://doi.org/10.1038/nrcardio.2010.186

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2010.186

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing